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Background: Clinical outcomes and cost-effectiveness of new technologies for hemodynamic support in patients with left ventricular dysfunction 
and complex anatomy have not been previously studied.
Methods: PROTECT II studied patients with 3 vessel disease and LV ejection fraction ≤ 30% or with unprotected left main/last patent conduit 
and LV ejection fraction ≤ 35% during PCI. Patients were randomized to either intra aortic balloon pump (IABP) or Impella (Abiomed). The primary 
endpoint was a composite of ten major adverse events (MAE) measured at 30 and 90 days. Economic analyses were performed to assess resource 
utilization for patients treated with Impella compared to IABP from index stay up to 90 days. Itemized hospital bills were collected for U.S. patients 
that consented for the economic study (N=260), converted to costs using department level cost-to-charge ratios, and modeled for the complete 
trial patient population at 90 days. Estimated costs were validated via comparison with MedPAR. Measures of episode-of-care costs, major adverse 
cardiac and cerebral events (MACCE), and Quality-Adjusted Life Years (QALYs) for both study arms served as inputs to a Markov model to estimate 
the incremental cost-effectiveness ratio (ICER).
Results: MAE at 90 days for Impella were 40.8% vs. IABP 51.4% (p=0.029) including a 51% relative reduction in repeat revascularization (Impella 
6.1% vs. IABP 12.4%, p=0.026). Improvement in ejection fraction and NYHA Class of heart failure were significant. Median hospital days for entire 
episode-of-care for Impella were 7 days vs. IABP 9 days (p=0.048). Reduction in MAE was associated with a gain in QALY for Impella patients. Base 
case ICER of $39,367 was well below the $100,000 value often given as a threshold for innovative technologies.
Conclusions: : For patients with severe LV dysfunction and complex anatomy, prophylactic use of Impella during PCI reduced MAE at an 
incremental cost per quality-adjusted life year considered to be cost-effective for advanced cardiovascular technologies. Improvements in overall 
quality of life metrics such as ejection fraction and NYHA Class of heart failure were significant in this study.
